Suppr超能文献

联合血管紧张素受体调节在心血管代谢紊乱管理中的应用

Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders.

作者信息

Paulis Ludovit, Foulquier Sébastien, Namsolleck Pawel, Recarti Chiara, Steckelings Ulrike Muscha, Unger Thomas

机构信息

Faculty of Medicine, Institute of Pathological Physiology, Comenius University in Bratislava, Sasinkova 4, 81108, Bratislava, Slovak Republic.

Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Sienkiewiczova 1, 81371, Bratislava, Slovak Republic.

出版信息

Drugs. 2016 Jan;76(1):1-12. doi: 10.1007/s40265-015-0509-4.

Abstract

Cardiovascular and metabolic disorders, such as hypertension, insulin resistance, dyslipidemia or obesity are linked with chronic low-grade inflammation and dysregulation of the renin-angiotensin system (RAS). Consequently, RAS inhibition by ACE inhibitors or angiotensin AT1 receptor (AT1R) blockers is the evidence-based standard for cardiovascular risk reduction in high-risk patients, including diabetics with albuminuria. In addition, RAS inhibition reduces the new onset of diabetes mellitus. Yet, the high and increasing prevalence of metabolic disorders, and the high residual risk even in properly treated patients, calls for additional means of pharmacological intervention. In the past decade, the stimulation of the angiotensin AT2 receptor (AT2R) has been shown to reduce inflammation, improve cardiac and vascular remodeling, enhance insulin sensitivity and increase adiponectin production. Therefore, a concept of dual AT1R/AT2R modulation emerges as a putative means for risk reduction in cardio-metabolic diseases. The approach employing simultaneous RAS blockade (AT1R) and RAS stimulation (AT2R) is distinct from previous attempts of double intervention in the RAS by dual blockade. Dual blockade abolishes the AT1R-linked RAS almost completely with subsequent risk of hypotension and hypotension-related events, i.e. syncope or renal dysfunction. Such complications might be especially prominent in patients with renal impairment or patients with isolated systolic hypertension and normal-to-low diastolic blood pressure values. In contrast to dual RAS blockade, the add-on of AT2R stimulation does not exert significant blood pressure effects, but it may complement and enhance the anti-inflammatory and antifibrotic/de-stiffening effects of the AT1R blockade and improve the metabolic profile. Further studies will have to investigate these putative effects in particular for settings in which blood pressure reduction is not primarily desired.

摘要

心血管和代谢紊乱,如高血压、胰岛素抵抗、血脂异常或肥胖,与慢性低度炎症及肾素-血管紧张素系统(RAS)失调有关。因此,对于包括有蛋白尿的糖尿病患者在内的高危患者,使用血管紧张素转换酶(ACE)抑制剂或血管紧张素AT1受体(AT1R)阻滞剂抑制RAS是降低心血管风险的循证标准。此外,抑制RAS可减少糖尿病的新发。然而,代谢紊乱的高患病率及其不断上升的趋势,以及即使在经过恰当治疗的患者中仍存在的高残留风险,都需要更多的药物干预手段。在过去十年中,已证实刺激血管紧张素AT2受体(AT2R)可减轻炎症、改善心脏和血管重塑、增强胰岛素敏感性并增加脂联素生成。因此,AT1R/AT2R双重调节的概念作为一种降低心脏代谢疾病风险的可能手段应运而生。同时进行RAS阻断(AT1R)和RAS刺激(AT2R)的方法不同于以往通过双重阻断对RAS进行双重干预的尝试。双重阻断几乎完全消除了与AT1R相关的RAS,随之而来的是低血压及与低血压相关事件(如晕厥或肾功能不全)的风险。此类并发症在肾功能受损患者或单纯收缩期高血压且舒张压正常至偏低的患者中可能尤为突出。与双重RAS阻断不同,添加AT2R刺激不会对血压产生显著影响,但它可能补充并增强AT1R阻断的抗炎和抗纤维化/去硬化作用,并改善代谢状况。未来的研究将尤其需要针对那些并非主要期望降低血压的情况来研究这些可能的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e246/4700059/fea275b3d26e/40265_2015_509_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验